Hannes Snellman Counsel to Charles River in Its Sale of Cobra Matfors to Flerie Invest
21 October 2021
Hannes Snellman acted as counsel to Charles River Laboratories International Inc. in its sale of Cobra Biologics Matfors AB to Flerie Invest for approximately USD 52,000,000 in cash, with potential contingent payments of up to an additional USD 25,000,000.
The Swedish investment company Flerie Invest’s acquisition and investment has been made with the intention of establishing an innovation hub for advanced vaccines and biological drugs in Matfors in northern Sweden. The site in Matfors will receive additional support from the Swedish Government through its innovation agency Vinnova. The new company will trade as NorthX Biologics.
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts. Charles River Laboratories International, Inc. is publicly traded on the New York Stock Exchange.
For further information, please refer to Charles River’s press release here.
Our core advisory team included Richard Åkerman and Douglas Essehorn (Private M&A).